Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG have signed an agreement to co-develop and market Confluence’s lead candidate in development for the treatment of Fragile X Syndrome in Europe and the Middle East. AOP, based in Austria, specializes in the development of medicines for rare and complex diseases.   Confluence received Orphan Designation in Europe and the U.S. for its lead product. The companies also anticipate an accelerated regulatory path to approval for Fragile X Synd...